Adult-onset  ||| S:0 E:12 ||| JJ
acral  ||| S:12 E:18 ||| JJ
peeling  ||| S:18 E:26 ||| JJ
skin  ||| S:26 E:31 ||| NN
syndrome  ||| S:31 E:40 ||| NN
in  ||| S:40 E:43 ||| IN
a  ||| S:43 E:45 ||| DT
non-identical  ||| S:45 E:59 ||| JJ
twin ||| S:59 E:63 ||| NN
:  ||| S:63 E:65 ||| :
a  ||| S:65 E:67 ||| DT
case  ||| S:67 E:72 ||| NN
report  ||| S:72 E:79 ||| NN
in  ||| S:79 E:82 ||| IN
South  ||| S:82 E:88 ||| NNP
Africa  ||| S:88 E:95 ||| NNP
Acral  ||| S:95 E:101 ||| NNP
peeling  ||| S:101 E:109 ||| JJ
skin  ||| S:109 E:114 ||| NN
syndrome  ||| S:114 E:123 ||| NN
is  ||| S:123 E:126 ||| VBZ
a  ||| S:126 E:128 ||| DT
rare  ||| S:128 E:133 ||| JJ
autosomal  ||| S:133 E:143 ||| JJ
recessive  ||| S:143 E:153 ||| JJ
disorder  ||| S:153 E:162 ||| NN
in  ||| S:162 E:165 ||| IN
which  ||| S:165 E:171 ||| WDT
skin  ||| S:171 E:176 ||| NN
exfoliation  ||| S:176 E:188 ||| NN
is  ||| S:188 E:191 ||| VBZ
limited  ||| S:191 E:199 ||| VBN
to  ||| S:199 E:202 ||| TO
the  ||| S:202 E:206 ||| DT
hands  ||| S:206 E:212 ||| NNS
and  ||| S:212 E:216 ||| CC
feet ||| S:216 E:220 ||| NNS
.  ||| S:220 E:222 ||| .
While  ||| S:222 E:228 ||| IN
it  ||| S:228 E:231 ||| PRP
typically  ||| S:231 E:241 ||| RB
manifests  ||| S:241 E:251 ||| VBN
from  ||| S:251 E:256 ||| IN
early  ||| S:256 E:262 ||| JJ
childhood ||| S:262 E:271 ||| NN
,  ||| S:271 E:273 ||| ,
in  ||| S:273 E:276 ||| IN
this  ||| S:276 E:281 ||| DT
first  ||| S:281 E:287 ||| JJ
reported  ||| S:287 E:296 ||| JJ
case  ||| S:296 E:301 ||| NN
from  ||| S:301 E:306 ||| IN
South  ||| S:306 E:312 ||| NNP
Africa ||| S:312 E:318 ||| NNP
,  ||| S:318 E:320 ||| ,
the  ||| S:320 E:324 ||| DT
patient  ||| S:324 E:332 ||| NN
did  ||| S:332 E:336 ||| VBD
not  ||| S:336 E:340 ||| RB
manifest  ||| S:340 E:349 ||| VBP
clinically  ||| S:349 E:360 ||| RB
until  ||| S:360 E:366 ||| IN
the  ||| S:366 E:370 ||| DT
fourth  ||| S:370 E:377 ||| JJ
decade  ||| S:377 E:384 ||| NN
of  ||| S:384 E:387 ||| IN
life ||| S:387 E:391 ||| NN
.  ||| S:391 E:393 ||| .
A  ||| S:393 E:395 ||| DT
44-year-old  ||| S:395 E:407 ||| JJ
woman  ||| S:407 E:413 ||| NN
of  ||| S:413 E:416 ||| IN
African  ||| S:416 E:424 ||| JJ
descent ||| S:424 E:431 ||| NN
,  ||| S:431 E:433 ||| ,
1  ||| S:433 E:435 ||| CD
of  ||| S:435 E:438 ||| IN
a  ||| S:438 E:440 ||| DT
set  ||| S:440 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
non-identical  ||| S:447 E:461 ||| JJ
twins ||| S:461 E:466 ||| NN
,  ||| S:466 E:468 ||| ,
presented  ||| S:468 E:478 ||| VBN
with  ||| S:478 E:483 ||| IN
recurrent  ||| S:483 E:493 ||| JJ
episodes  ||| S:493 E:502 ||| NNS
of  ||| S:502 E:505 ||| IN
skin  ||| S:505 E:510 ||| NN
peeling  ||| S:510 E:518 ||| NN
of  ||| S:518 E:521 ||| IN
the  ||| S:521 E:525 ||| DT
upper  ||| S:525 E:531 ||| JJ
and  ||| S:531 E:535 ||| CC
lower  ||| S:535 E:541 ||| JJR
limbs ||| S:541 E:546 ||| NNS
.  ||| S:546 E:548 ||| .
The  ||| S:548 E:552 ||| DT
first  ||| S:552 E:558 ||| JJ
episode  ||| S:558 E:566 ||| NN
occurred  ||| S:566 E:575 ||| VBD
4  ||| S:575 E:577 ||| CD
years  ||| S:577 E:583 ||| NNS
prior ||| S:583 E:588 ||| RB
,  ||| S:588 E:590 ||| ,
followed  ||| S:590 E:599 ||| VBN
by  ||| S:599 E:602 ||| IN
perennial  ||| S:602 E:612 ||| JJ
skin  ||| S:612 E:617 ||| NN
peeling  ||| S:617 E:625 ||| NN
during  ||| S:625 E:632 ||| IN
the  ||| S:632 E:636 ||| DT
spring  ||| S:636 E:643 ||| NN
seasons ||| S:643 E:650 ||| NNS
.  ||| S:650 E:652 ||| .
She  ||| S:652 E:656 ||| PRP
was  ||| S:656 E:660 ||| VBD
not  ||| S:660 E:664 ||| RB
on  ||| S:664 E:667 ||| IN
treatment  ||| S:667 E:677 ||| NN
for  ||| S:677 E:681 ||| IN
any  ||| S:681 E:685 ||| DT
chronic  ||| S:685 E:693 ||| JJ
disease  ||| S:693 E:701 ||| NN
and  ||| S:701 E:705 ||| CC
reported  ||| S:705 E:714 ||| VBD
no  ||| S:714 E:717 ||| DT
exposure  ||| S:717 E:726 ||| NN
to  ||| S:726 E:729 ||| TO
chemicals  ||| S:729 E:739 ||| NNS
or  ||| S:739 E:742 ||| CC
other  ||| S:742 E:748 ||| JJ
irritants ||| S:748 E:757 ||| NN
.  ||| S:757 E:759 ||| .
The  ||| S:759 E:763 ||| DT
family ||| S:763 E:769 ||| NN
,  ||| S:769 E:771 ||| ,
including  ||| S:771 E:781 ||| VBG
the  ||| S:781 E:785 ||| DT
non-identical  ||| S:785 E:799 ||| JJ
twin  ||| S:799 E:804 ||| JJ
sister ||| S:804 E:810 ||| NN
,  ||| S:810 E:812 ||| ,
has  ||| S:812 E:816 ||| VBZ
no  ||| S:816 E:819 ||| DT
history  ||| S:819 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
skin  ||| S:830 E:835 ||| NN
disorders  ||| S:835 E:845 ||| NNS
and  ||| S:845 E:849 ||| CC
the  ||| S:849 E:853 ||| DT
patient ||| S:853 E:860 ||| NN
's  ||| S:860 E:863 ||| POS
HIV  ||| S:863 E:867 ||| NNP
antibody  ||| S:867 E:876 ||| NN
test  ||| S:876 E:881 ||| NN
was  ||| S:881 E:885 ||| VBD
negative ||| S:885 E:893 ||| JJ
.  ||| S:893 E:895 ||| .
At  ||| S:895 E:898 ||| IN
presentation ||| S:898 E:910 ||| NN
,  ||| S:910 E:912 ||| ,
physical  ||| S:912 E:921 ||| JJ
examination  ||| S:921 E:933 ||| NN
revealed  ||| S:933 E:942 ||| VBD
ongoing  ||| S:942 E:950 ||| JJ
exfoliation  ||| S:950 E:962 ||| NN
with  ||| S:962 E:967 ||| IN
new  ||| S:967 E:971 ||| JJ
skin  ||| S:971 E:976 ||| NN
formation  ||| S:976 E:986 ||| NN
on  ||| S:986 E:989 ||| IN
the  ||| S:989 E:993 ||| DT
palms  ||| S:993 E:999 ||| NNS
and  ||| S:999 E:1003 ||| CC
soles ||| S:1003 E:1008 ||| NN
.  ||| S:1008 E:1010 ||| .
The  ||| S:1010 E:1014 ||| DT
mucous  ||| S:1014 E:1021 ||| JJ
membranes  ||| S:1021 E:1031 ||| NN
and  ||| S:1031 E:1035 ||| CC
nails  ||| S:1035 E:1041 ||| NNS
were  ||| S:1041 E:1046 ||| VBD
spared ||| S:1046 E:1052 ||| VBN
.  ||| S:1052 E:1054 ||| .
Other  ||| S:1054 E:1060 ||| JJ
systems  ||| S:1060 E:1068 ||| NNS
were  ||| S:1068 E:1073 ||| VBD
normal ||| S:1073 E:1079 ||| JJ
.  ||| S:1079 E:1081 ||| .
Skin  ||| S:1081 E:1086 ||| NN
biopsy  ||| S:1086 E:1093 ||| VBZ
taken  ||| S:1093 E:1099 ||| VBN
from  ||| S:1099 E:1104 ||| IN
the  ||| S:1104 E:1108 ||| DT
palms  ||| S:1108 E:1114 ||| NNS
confirmed  ||| S:1114 E:1124 ||| VBD
peeling  ||| S:1124 E:1132 ||| JJ
skin  ||| S:1132 E:1137 ||| NN
syndrome ||| S:1137 E:1145 ||| NN
.  ||| S:1145 E:1147 ||| .
The  ||| S:1147 E:1151 ||| DT
patient  ||| S:1151 E:1159 ||| NN
was  ||| S:1159 E:1163 ||| VBD
managed  ||| S:1163 E:1171 ||| VBN
with  ||| S:1171 E:1176 ||| IN
topical  ||| S:1176 E:1184 ||| JJ
aqueous  ||| S:1184 E:1192 ||| JJ
cream  ||| S:1192 E:1198 ||| NN
and  ||| S:1198 E:1202 ||| CC
analgesics ||| S:1202 E:1212 ||| NN
.  ||| S:1212 E:1214 ||| .
She  ||| S:1214 E:1218 ||| PRP
was  ||| S:1218 E:1222 ||| VBD
briefly  ||| S:1222 E:1230 ||| RB
counseled  ||| S:1230 E:1240 ||| VBN
on  ||| S:1240 E:1243 ||| IN
the  ||| S:1243 E:1247 ||| DT
nature  ||| S:1247 E:1254 ||| NN
and  ||| S:1254 E:1258 ||| CC
prognosis  ||| S:1258 E:1268 ||| NN
of  ||| S:1268 E:1271 ||| IN
the  ||| S:1271 E:1275 ||| DT
disease ||| S:1275 E:1282 ||| NN
,  ||| S:1282 E:1284 ||| ,
and  ||| S:1284 E:1288 ||| CC
referred  ||| S:1288 E:1297 ||| VBD
for  ||| S:1297 E:1301 ||| IN
genetic  ||| S:1301 E:1309 ||| JJ
testing  ||| S:1309 E:1317 ||| NN
and  ||| S:1317 E:1321 ||| CC
counseling ||| S:1321 E:1331 ||| NN
.  ||| S:1331 E:1333 ||| .
On  ||| S:1333 E:1336 ||| IN
follow-up ||| S:1336 E:1345 ||| NNP
,  ||| S:1345 E:1347 ||| ,
she  ||| S:1347 E:1351 ||| PRP
continues  ||| S:1351 E:1361 ||| VBZ
to  ||| S:1361 E:1364 ||| TO
have  ||| S:1364 E:1369 ||| VB
skin  ||| S:1369 E:1374 ||| NN
peeling  ||| S:1374 E:1382 ||| VBZ
once  ||| S:1382 E:1387 ||| RB
or  ||| S:1387 E:1390 ||| CC
twice  ||| S:1390 E:1396 ||| RB
a  ||| S:1396 E:1398 ||| DT
year ||| S:1398 E:1402 ||| NN
.  ||| S:1402 E:1404 ||| .
This  ||| S:1404 E:1409 ||| DT
first  ||| S:1409 E:1415 ||| JJ
reported  ||| S:1415 E:1424 ||| JJ
case  ||| S:1424 E:1429 ||| NN
of  ||| S:1429 E:1432 ||| IN
this  ||| S:1432 E:1437 ||| DT
rare  ||| S:1437 E:1442 ||| JJ
disease  ||| S:1442 E:1450 ||| NN
in  ||| S:1450 E:1453 ||| IN
South  ||| S:1453 E:1459 ||| NNP
Africa  ||| S:1459 E:1466 ||| NNP
contributes  ||| S:1466 E:1478 ||| VBZ
to  ||| S:1478 E:1481 ||| TO
the  ||| S:1481 E:1485 ||| DT
growing  ||| S:1485 E:1493 ||| VBG
body  ||| S:1493 E:1498 ||| NN
of  ||| S:1498 E:1501 ||| IN
literature  ||| S:1501 E:1512 ||| NN
on  ||| S:1512 E:1515 ||| IN
the  ||| S:1515 E:1519 ||| DT
disease  ||| S:1519 E:1527 ||| NN
and  ||| S:1527 E:1531 ||| CC
highlights  ||| S:1531 E:1542 ||| VBZ
the  ||| S:1542 E:1546 ||| DT
need  ||| S:1546 E:1551 ||| NN
for  ||| S:1551 E:1555 ||| IN
clinicians  ||| S:1555 E:1566 ||| VBG
to  ||| S:1566 E:1569 ||| TO
be  ||| S:1569 E:1572 ||| VB
aware  ||| S:1572 E:1578 ||| JJ
of  ||| S:1578 E:1581 ||| IN
its  ||| S:1581 E:1585 ||| PRP$
variable  ||| S:1585 E:1594 ||| JJ
clinical  ||| S:1594 E:1603 ||| JJ
onset ||| S:1603 E:1608 ||| NN
.  ||| S:1608 E:1610 ||| .
